PT1838318E - Utilização de oxicodona para o tratamento da dor visceral - Google Patents

Utilização de oxicodona para o tratamento da dor visceral Download PDF

Info

Publication number
PT1838318E
PT1838318E PT06700652T PT06700652T PT1838318E PT 1838318 E PT1838318 E PT 1838318E PT 06700652 T PT06700652 T PT 06700652T PT 06700652 T PT06700652 T PT 06700652T PT 1838318 E PT1838318 E PT 1838318E
Authority
PT
Portugal
Prior art keywords
oxycodone
visceral pain
treating visceral
treating
pain
Prior art date
Application number
PT06700652T
Other languages
English (en)
Portuguese (pt)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1838318(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PT1838318E publication Critical patent/PT1838318E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
PT06700652T 2005-01-18 2006-01-17 Utilização de oxicodona para o tratamento da dor visceral PT1838318E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
PT1838318E true PT1838318E (pt) 2009-12-15

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06700652T PT1838318E (pt) 2005-01-18 2006-01-17 Utilização de oxicodona para o tratamento da dor visceral

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20200128451A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE602006009899D1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
RU2535074C2 (ru) * 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
TWI692485B (zh) 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
KR102128628B1 (ko) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
RS51069B (sr) 2010-10-31
KR20200128451A (ko) 2020-11-12
DK200700207U3 (da) 2007-09-28
CN101106996B (zh) 2013-10-23
KR20120089710A (ko) 2012-08-13
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
CA2595043C (en) 2013-11-19
MY144471A (en) 2011-09-30
DK200700207U1 (da) 2007-08-24
DK1838318T3 (da) 2010-01-04
US20080200493A1 (en) 2008-08-21
KR20230170811A (ko) 2023-12-19
NO338968B1 (no) 2016-11-07
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
NO20074174L (no) 2007-10-17
ES2333901T3 (es) 2010-03-02
KR20070100368A (ko) 2007-10-10
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DE602006009899D1 (de) 2009-12-03
SI1838318T1 (sl) 2010-02-26
ME01066B (me) 2012-10-20
IL184530A0 (en) 2007-10-31
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
NZ555852A (en) 2010-01-29
TWI432196B (zh) 2014-04-01
EA200701541A1 (ru) 2008-02-28
HRP20090679T1 (hr) 2010-01-31
AP2007004057A0 (en) 2007-08-31
AT9895U1 (de) 2008-05-15
KR20190135557A (ko) 2019-12-06
CA2595043A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
CY1109660T1 (el) 2014-08-13
KR20080106991A (ko) 2008-12-09
WO2006077212A1 (en) 2006-07-27
AU2006207498A1 (en) 2006-07-27
AP2249A (en) 2011-07-18
DE202006019887U1 (de) 2007-07-26
IL184530A (en) 2015-01-29
AR052880A1 (es) 2007-04-11
CN101106996A (zh) 2008-01-16
JP2008526927A (ja) 2008-07-24
BRPI0606247A2 (pt) 2009-06-09
AU2006207498B2 (en) 2009-11-19
JP5049139B2 (ja) 2012-10-17
PL1838318T3 (pl) 2010-03-31
ZA200705231B (en) 2008-06-25
KR20220165797A (ko) 2022-12-15
KR20140091782A (ko) 2014-07-22
TW200637554A (en) 2006-11-01
KR20210131450A (ko) 2021-11-02
EA013544B1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
ZA200705231B (en) Use of oxycodone for treating visceral pain
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
IL248204A0 (en) Combined treatment of tumors expressing 38cd
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
IL188430A0 (en) Treatment of tumors
IL193460A0 (en) Compounds and methods for treatment of stroke
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
IL201422A0 (en) Therapeutic agents useful for treating pain
GB0404656D0 (en) Treatment of spinal conditions
EP1928452A4 (en) USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
ZA200904478B (en) Novel therapeutic use for treating leukaemia
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
GB0610868D0 (en) Treatment of pain
EP1813271A4 (en) PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN
GB0408521D0 (en) Treatment of sepsis
GB0616450D0 (en) Treatment of pain
GB0623740D0 (en) Treatment of disease
IL189077A0 (en) Novel use of peptide compounds for treating muscle pain